霉酚酸酯治疗重症肌无力：一项开放标签的试点研究。
Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.
作者信息
Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B
机构信息
Division of Neurology, Duke University Medical Center, Durham, NC, USA.
出版信息
Neurology. 2001 Jan 9;56(1):97-9. doi: 10.1212/wnl.56.1.97.
In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed.
在一项开放标签研究中，12例难治性重症肌无力患者或仅服用皮质类固醇且需要额外免疫抑制的患者，接受霉酚酸酯治疗，剂量为每日2次，每次1 g，持续6个月。疗效定义为定量重症肌无力评分降低3分、徒手肌力测试降低2分或皮质类固醇剂量降低50%。8例患者在2周~2个月后开始改善。未观察到严重副作用。
Zotero 插件